Surgery
Volume 146, Issue 2 , Pages 296-299 , August 2009

Two hundred and two consecutive operations for secondary hyperparathyroidism: Has medical management changed the profiles of patients requiring parathyroidectomy?

,Accepted 17 March 2009.

References 

  1. Matsuoka S, Tominaga Y, Uno N, Goto N, Sato T, Katayama A, et al Calciphylaxis: a rare complication of patients who required parathyroidectomy for advanced renal hyperparathyroidism. World J Surg. 2005;29:632–635
  2. Elder GJ. Parathyroidectomy in the calcimimetic era. Nephrology (Carlton). 2005;10:511–515
  3. Costa-Hong V, Jorgetti V, Gowdak LH, Moyses RM, Krieger EM, De Lima JJ. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery. 2007;142:699–703
  4. Milas M, Weber CJ. Near-total parathyroidectomy is beneficial for patients with secondary and tertiary hyperparathyroidism. Surgery. 2004;136:1252–1260
  5. Richards ML, Wormuth J, Bingener J, Sirinek K. Parathyroidectomy in secondary hyperparathyroidism: is there an optimal operative management?. Surgery. 2006;139:174–180
  6. Shih ML, Duh QY, Hsieh CB, et al. Total parathyroidectomy without autotransplantation for secondary hyperparathyroidism. World J Surg. 2009;33:248–254
  7. Kestenbaum B, Seliger SL, Gillen DL, Wasse H, Young B, Sherrard DJ, et al. Parathyroidectomy rates among United States dialysis patients: 1990–1999. Kidney Int. 2004;65:282–288
  8. Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol. 2005;16:210–218
  9. Lomonte C, Antonelli M, Losurdo N, Marchio G, Giammaria B, Basile C. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy. Nephrol Dial Transplant. 2007;22:2056–2062
  10. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–1525
  11. Sterrett JR, Strom J, Stummvoll HK, Bahner U, Disney A, Soroka SD, et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2007;68:10–17

PII: S0039-6060(09)00250-5

doi: 10.1016/j.surg.2009.03.032

Surgery
Volume 146, Issue 2 , Pages 296-299 , August 2009

Article Tools